258 related articles for article (PubMed ID: 11158091)
1. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
[TBL] [Abstract][Full Text] [Related]
2. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
5. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
6. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
7. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
8. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
9. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
10. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
[TBL] [Abstract][Full Text] [Related]
12. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
Stoddart CA; Liegler TJ; Mammano F; Linquist-Stepps VD; Hayden MS; Deeks SG; Grant RM; Clavel F; McCune JM
Nat Med; 2001 Jun; 7(6):712-8. PubMed ID: 11385509
[TBL] [Abstract][Full Text] [Related]
13. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
14. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.
Kapoor A; Jones M; Shafer RW; Rhee SY; Kazanjian P; Delwart EL
J Virol; 2004 Jul; 78(13):7112-23. PubMed ID: 15194787
[TBL] [Abstract][Full Text] [Related]
15. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
16. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
Condra JH; Schleif WA; Blahy OM; Gabryelski LJ; Graham DJ; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M
Nature; 1995 Apr; 374(6522):569-71. PubMed ID: 7700387
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
20. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]